Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of N8-GP for prophylaxis and treatment of bleeding in severe haemophilia A
NL-OMON43797Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of octocog alfa in hemophilia A (3 arms), sponsored by Novo Nordisk. Primary endpoints: Incidence of factor VIII inhibitors and Annualised bleeding rate during prophylaxis. Started Jul 2012; status: active, not recruiting.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON43797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43797.